secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001367644-25-000179
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions Q2 revenue $140.9M, beats guidance; raises FY profitability outlook
--------------------------------------------------------------------------------

- Q2 revenue $140.9M (above Q2 guidance by $21M); net loss improved to $12.0M from $283.1M loss a year ago.
- Adjusted EBITDA swung to $28.5M from ($10.1M) loss; adjusted gross margin expanded to 49% from 26%.
- Naloxone revenue down 44% to $67.5M; Smallpox MCM up 127% to $40.6M; Anthrax MCM down 70%.
- Raised FY2025 adjusted EBITDA guidance to $175-$200M (prev. $150-$200M); adjusted gross margin 50-52%.
- Secured $65M multi-year NARCAN contract with Ontario Ministry of Health and $114.3M in contract modifications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000179/0001367644-25-000179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000179/ebs-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001367644-25-000179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer